20+ years of experience advising corporate clients on federal tax matters
Helps clients claim, document and sustain tax incentives, including research tax credits and investment tax credits
Advises Fortune 500 clients in aerospace and defense, food products, manufacturing and software industries
San Francisco
@alvarezmarsal
LinkedIn
Copied!
Brett Nowak is a Managing Director with Alvarez & Marsal Tax in San Francisco.
With more than 20 years of experience advising corporate clients on federal tax matters, Mr. Nowak helps clients claim, document and sustain tax incentives, including research tax credits and investment tax credits. These reviews have ranged from sophisticated multi-year claims to isolated consulting projects.
Mr. Nowak has advised numerous Fortune 500 clients across a variety of industries including aerospace and defense, biotechnology, pharmaceuticals, food products, manufacturing and software.
Prior to joining A&M, Mr. Nowak was a manager with KPMG, where he served as a Regional Leader for the Research Credit Services team.
Previously, Mr. Nowak was with Arthur Andersen. He was also a member of each firm’s national Research Tax Incentives team.
Mr. Nowak earned a bachelor’s degree in accounting from the University of Illinois and a J.D. from Vanderbilt University. He is a member of the Illinois Bar.
On September 8th, Treasury and the IRS released Notice 2023-63 (the Notice), which showcased the rules they intend to propose regarding the mandatory requirement to capitalize and amortize specified research or experimental (SRE) costs under section 174, which became effective beginning in 2022.
The transition to capitalizing research and experimental costs under section 174 has been fraught with increasingly complex issues without much-needed guidance to resolve them.
As a result of the Tax Cuts and Jobs Act (TCJA), beginning with tax years after December 31, 2021, Section 174 requires taxpayers to capitalize and amortize research and experimental expenditures.
